There was statistically significant evidence of a larger difference between DTG and comparator among participants with a higher viral load.
The proportion of patients with bacteraemia (∼25%) is similar to the other studies in this review, but their broad definition of adverse medical outcomes, as found in ∼50% of cases, does not have a direct comparator among the Western European/North American studies reviewed, therefore no accurate conclusion can be reached.
Similarly, outcomes were better for thrombolysed patients versus nonthrombolysed comparators among who have not had a prior stroke (P < 0.0001; 1.4 [1.2–1.6 ]) and those who have (P = 0.02; 1.3 [1.04–1.6 ]).
Functional outcomes were better for thrombolysed patients versus nonthrombolysed comparators among both nondiabetic (P < 0.0001; OR 1.4 [95% CI 1.3 1.6]) and diabetic (P = 0.1; 1.3 [1.05–1.6 ]) subjects.
This attractive hypothesis does not easily account for the observation from clinical trials, discussed above, that aspirin use does not appear to have influenced the relation of cardiovascular event rates observed between COX-2 inhibitors and comparators among patients in randomized trials.
In each trial, ORR was significantly higher for nab-paclitaxel versus the comparator taxane among patients with visceral dominant metastases.
44 45 47 49 Comparator interventions among studies with primary data collection were self-help materials (four studies); 41 43 48 52 brief advice (four studies); 41 48 51 52 and standard UK National Health Service treatment (see online supplementary file 3 for details) (two studies).
The composite therapy was operationalized by averaging the discontinuation rates (transition probabilities), costs, and outcomes of the other comparator AAPs among which the patient might possibly switch (eg, if a patient initiates treatment with lurasidone, then the composite would reflect the average of aripiprazole, olanzapine, quetiapine extended-release, risperidone, and ziprasidone).
Protection against severe malaria is an important objective of malaria vaccine efforts; however, too few cases of severe malaria (according-to-protocol cohort: one case among FMP1/AS02 and two among comparator recipients; intention-to-treat cohort: nine and five cases, respectively) occurred in the present study to allow assessment of this.
Nonetheless, both that study and ours suggest greater metabolic risk at lower BMI cut-points among the two ethnic groups than among comparator populations of European origin.
The massive study on Gender in the Global Research Landscape, published today by Elsevier, identifies 12 "comparator" countries, including among them the United States, the European Union (counted as one), the United Kingdom, Portugal, Chile, Mexico, and Brazil.
